Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myelomaAntonio Palumbo
Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Ospedale Molinette, Italy
Clin Lymphoma Myeloma 6:475-7. 2006
..Bortezomib and thalidomide have shown synergy with melphalan and dexamethasone. We used this 4-drug combination as conditioning before autologous hematopoietic cell infusions...
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myelomaMarco Ladetto
Cattedra di Ematologia, Via Genova 3, 10126 Torino, Italy
J Clin Oncol 28:2077-84. 2010
..Moreover, the major reduction in tumor load recorded by RQ-PCR after VTD suggests that unprecedented levels of tumor cell reduction can be achieved in MM thanks to the new nonchemotherapeutic drugs...
- Management of older adults with multiple myeloma
Antonio Palumbo
Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy Electronic address
Blood Rev 27:133-42. 2013
..In this setting, less toxic regimens and appropriate dose reductions should be adopted. Here we provide an overview of novel agent-based treatment strategies for elderly patients with multiple myeloma...
- Have drug combinations supplanted stem cell transplantation in myeloma?
Antonio Palumbo
Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy
Hematology Am Soc Hematol Educ Program 2012:335-41. 2012
..This article provides an overview of recent and ongoing clinical trials and aims to define the role of ASCT in the era of novel agents...
- Part II: role of maintenance therapy in transplant-ineligible patients
Antonio Palumbo
Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy
J Natl Compr Canc Netw 11:43-9. 2013
..This article provides an overview of the main trials including consolidation/maintenance therapy after induction for transplant-ineligible patients. Recommendations on how to manage treatment-related toxicities are also provided...
- Have drug combinations supplanted stem cell transplantation in myeloma?
Antonio Palumbo
Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy
Blood 120:4692-8. 2012
..This article provides an overview of recent and ongoing clinical trials and aims to define the role of ASCT in the era of novel agents...
Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trialsAntonio Palumbo
Myeloma Unit, Division of Hematology, University of Turin, AOU S Giovanni Battista, Torino, Italy
Haematologica 98:87-94. 2013
..Serious non-hematologic toxicities, older age, poor Performance Status, and high creatinine levels negatively affected survival...
- Sustained disease control in transplant-ineligible patients: the role of continuous therapy
Antonio Palumbo
Myeloma Unit, Division of Hematology, University of Turin, Azienda Ospedaliero Universitaria, San Giovanni Battista di Torino, Turin, Italy
Leuk Res 36:S19-26. 2012
....
- Continuous lenalidomide treatment for newly diagnosed multiple myeloma
Antonio Palumbo
Myeloma Unit, Division of Hematology, University of Turin, Azienda Ospedaliero Universitaria, S Giovanni Battista, Via Genova 3, 10126 Turin, Italy
N Engl J Med 366:1759-69. 2012
....
- How to manage neutropenia in multiple myeloma
Antonio Palumbo
Myeloma Unit, Division of Hematology, University of Torino, AOU San Giovanni Battista, Turin, Italy
Clin Lymphoma Myeloma Leuk 12:5-11. 2012
..If ANC restores to > 1000 cells/mL, therapy can be resumed with no dose modifications. In case of persistence of severe neutropenia, treatment should be delayed until ANC reaches > 1000 cells/mL, and dose reductions are necessary...
- Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients
Antonio Palumbo
Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliero Universitaria San Giovanni Battista, Via Genova 3, 10126 Torino, Italy
J Clin Oncol 28:800-7. 2010
..CONCLUSION Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance, is an effective regimen...
- Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy
Antonio Palumbo
Division of Hematology, University of Torino, San Giovanni Battista Hospital, Turin, Italy
Cancer 110:824-9. 2007
..Baseline parameters that may be predictive of outcome after thalidomide treatment have been investigated to identify which myeloma patient subgroups will most benefit from this drug...
- Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial
Antonio Palumbo
Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero Universitaria A O U S Giovanni Battista, Torino, Italy
J Clin Oncol 28:5101-9. 2010
....
- Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network
Antonio Palumbo
Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
J Clin Oncol 25:4459-65. 2007
..We assessed dosing, efficacy, and safety of melphalan, prednisone, and lenalidomide (MPR) in newly diagnosed elderly myeloma patients...
- A new standard of care for elderly patients with myeloma
Antonio Palumbo
, Azienda Ospedaliera San Giovanni Battista, Torino 10126, Italy
Lancet 370:1191-2. 2007
- Treatment of newly diagnosed multiple myeloma
Antonio Palumbo
Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Via Genova 3, Turin, Italy
Curr Hematol Malig Rep 3:107-14. 2008
..The introduction of thalidomide, bortezomib, and lenalidomide, which target MM cells and the bone marrow microenvironment, has changed the therapeutic options in newly diagnosed patients with MM...
- Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
A Palumbo
Division of Hematology, University of Turin, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
Leukemia 22:414-23. 2008
..Further investigation is needed to define the best VTE prophylaxis...
- Lenalidomide: a new therapy for multiple myeloma
Antonio Palumbo
Department of Hematology, University of Torino, Ospedale Molinette, Via Genova 3, 10126 Torino, Italy
Cancer Treat Rev 34:283-91. 2008
....
- Thalidomide for treatment of multiple myeloma: 10 years later
Antonio Palumbo
Division of Hematology, University of Torino, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
Blood 111:3968-77. 2008
..Future studies will define the most effective or the best sequence of combinations which could improve life expectancy...
- Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma
A Palumbo
Divisione di Ematologia dell Universita di Torino, AOU S Giovanni Battista, Turin, Italy
Leukemia 24:1037-42. 2010
..In conclusion, RMPT is an active salvage therapy with good efficacy and manageable side effects. This study represents the basis for larger phase III randomized trials...
- Treatment of newly diagnosed myeloma
A Palumbo
Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Ospedale Molinette, Turin, Italy
Leukemia 23:449-56. 2009
..If these data will be confirmed, a cytogenetically risk-adapted strategy might become the most appropriate strategy...
- Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma
A Palumbo
Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
Ann Oncol 19:1160-5. 2008
..Bortezomib has shown significant activity in myeloma. In this multicenter trial, we assessed for the first time the combination of bortezomib, doxorubicin and low-dose dexamethasone (PAd) in the treatment of relapsed/refractory myeloma...
- International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation
A Palumbo
Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Ospedale Molinette, Torino 10126, Italy
Leukemia 23:1716-30. 2009
..These guidelines will aid the physician in daily clinical practice and will ensure optimal care for patients with MM...
- Update on recent developments for patients with newly diagnosed multiple myeloma
Antonio Palumbo
Divisione di Ematologia dell Universita di Torino, Torino, Italy
Ann N Y Acad Sci 1138:19-21. 2008
..Combination regimens containing bortezomib or thalidomide can achieve response rates, especially complete response rates, which are superior to those seen with standard MP alone, and offer new possibilities for this patient population...
- Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma
A Palumbo
University of Torino, Turin, Italy
Ann Hematol 89:803-11. 2010
....
- Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma
Antonio Palumbo
Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Turin, Italy
Blood Rev 23:87-93. 2009
..The recommendations presented here will aid the safe administration of lenalidomide, and avoid unnecessary dose reduction and discontinuation, thus assuring the best efficacy of treatment...
- Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial
Antonio Palumbo
Divisione, di Ematologia Dell Università di Torino, Azienda Ospedaliera San, Giovanni Battista, Via Genova 3, 10126 Torino, Italy
Haematologica 95:1144-9. 2010
....
- Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study
Antonio Palumbo
Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliero Universitaria S Giovanni Battista, Via Genova 3, 10126 Torino, Italy
Blood 115:1873-9. 2010
..We conclude that MEL200 leads to longer remission duration and should be considered the standard conditioning regimen for autologous transplantation. This study was registered at www.clinicaltrials.gov as #NCT00950768...
- Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results
Antonio Palumbo
Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
Clin Lymphoma Myeloma 9:145-50. 2009
..This updated analysis reassessed the kinetics of neutropenia and thrombocytopenia as well as the safety and efficacy of MPR...
- Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival
Antonio Palumbo
Myeloma Unit, Division of Hematology, University of Turin, Turin, Italy
Clin Cancer Res 17:1253-63. 2011
..Physicians now have a wider variety of treatment options to tailor the most appropriate and efficacious treatment according to their patients' characteristics...
- The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes
Antonio Palumbo
Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Via Genova 3, 10126 Turin, Italy
Expert Opin Drug Saf 11:107-20. 2012
....
- Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial
Antonio Palumbo
Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, 10126 Torino, Italy
Lancet 367:825-31. 2006
..This multicentre randomised trial compared oral MP plus thalidomide (MPT) with MP alone in patients aged 60-85 years...
- Multiple myeloma: chemotherapy or transplantation in the era of new drugs
Antonio Palumbo
Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Torino, Italy
Eur J Haematol 84:379-90. 2010
..Compared with standard chemotherapy, a survival benefit has been reported for the first time in 30 yrs...
- Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)
Antonio Palumbo
Division of Hematology, University of Torino, Azinda Ospedaliero Universitaria S Giovanni Battista, Torino, Italy
Blood 118:4519-29. 2011
..Similarly, occurrence of serious nonhematologic adverse events during treatment should be carefully taken into account to adjust doses and optimize outcomes...
- Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma
Antonio Palumbo
Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera AO S Giovanni Battista, Turin, Italy
Blood 109:2767-72. 2007
..Initial results showed that VMPT is an effective salvage therapy with a very high proportion of responses. The incidence of neurotoxicities was unexpectedly low...
- Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?
Antonio Palumbo
Myeloma Unit, University of Torino, Azienda Ospedaliero Universitaria A O U S Giovanni Battista, Italy
Blood Rev 25:181-91. 2011
....
- Dose reduction in spiral CT coronary angiography with dual-source equipment. Part I. A phantom study applying different prospective tube current modulation algorithms
C Martini
Dipartimento di Radiologia e Cardiologia, Azienda Ospedaliero Universitaria, Parma, Italy
Radiol Med 114:1037-52. 2009
..The authors sought to compare different algorithms for dose reduction in retrospectively echocardiographically (ECG)-gated dual-source computed tomography (CT) coronary angiography (DSCT-CA) in a phantom model...
- Prognostic value of Morise clinical score, calcium score and computed tomography coronary angiography in patients with suspected or known coronary artery disease
E Maffei
Department of Radiology and Cardiology, Azienda Ospedaliero Universitaria, Parma, Italy
Radiol Med 116:1188-202. 2011
..Our aim was to determine the prognostic value of computed tomography coronary angiography (CTCA), coronary artery calcium scoring (CACS) and Morise clinical score in patients with known or suspected coronary artery disease (CAD)...
- Functional parameters of the left ventricle: comparison of cardiac MRI and cardiac CT in a large population
A Palumbo
Dipartimento di Radiologia e Cardiologia, Azienda Ospedaliero Universitaria, Parma, Italy
Radiol Med 115:702-13. 2010
..The authors sought to compare magnetic resonance imaging (MRI) and computed tomography (CT) for assessing left ventricular (LV) function parameters in a large patient population...
- Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma
Antonio Palumbo
Divisione di Ematologia, , Azienda Ospedaliera S. Giovanni Battista, Ospedale Molinette, Turin, Italy
Eur J Haematol 76:273-7. 2006
..CONCLUSIONS: M(i.v.)PT is an effective regimen, which can overcome resistance to thalidomide plus prednisone in advanced myeloma with acceptable toxicity...
- Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m(2))
A Palumbo
, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
Leukemia 18:133-8. 2004
..The intensified nonmyeloablative MEL100 regimen is an effective first-line treatment...
- Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma
A Palumbo
, Azienda Ospedaliera S. Giovanni Battista, Torino, Italy
Haematologica 86:399-403. 2001
..A significant proportion of patients benefit from this treatment as a salvage therapy postponing the delivery of chemotherapy...
- Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma
Mario Boccadoro
Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Via Genova 3, 10126 Turin, Italy
Haematologica 87:846-50. 2002
....
- Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma
Antonio Palumbo
, Azienda Ospedaliera S. Giovanni Battista, Turin, Italy
Cancer 104:1428-33. 2005
..Administration of prophylactic anticoagulant was required to prevent thromboembolism. MPT merits further investigation in randomized clinical trials...
- The future role of thalidomide in multiple myeloma
Mario Boccadoro
Divisione di Ematologia, Ospedale Molinette, Torino, Italy
Acta Haematol 114:18-22. 2005
..The workshop acknowledged the problems associated with designing a phase III study, and it is clear that many areas need to be addressed in the use of thalidomide for the treatment of multiple myeloma...
- Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant
Antonio Palumbo
, Torino, Italy
Eur J Haematol 75:391-5. 2005
..5 months) (P = 0.008). Multivariate analysis indicated that TD and age were the only independent risk factors associated with improved outcome. CONCLUSION: TD improved PFS and OS in myeloma patients relapsing after AT...
- Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
Antonio Palumbo
Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
Blood 112:3107-14. 2008
..34). These data confirm activity of MPT for PFS but failed to show any survival advantage. New agents in the management of relapsed disease could explain this finding. The study is registered at www.clinicaltrials.gov as #NCT00232934...
- Investigational treatments for multiple myeloma
Sara Bringhen
, Azienda Ospedaliera San Giovanni Battista, Via Genova 3, 10126 Torino, Italy
Expert Opin Investig Drugs 15:1565-82. 2006
..Their mechanisms of action, the available knowledge on their efficacy, safety and possible future clinical application are reviewed...
- Computed tomography coronary angiography in asymptomatic patients
E Maffei
Department of Radiology and Cardiology, c o Piastra Tecnica, Piano 0, Azienda Ospedaliero Universitaria, Via Gramsci 14, 43100, Parma, Italy
Radiol Med 116:1161-73. 2011
..This study assessed the accuracy of computed tomography coronary angiography (CT-CA) for detecting significant coronary artery disease (CAD; ≥50% lumen reduction) in intermediate/high-risk asymptomatic patients...
- Multiple myeloma: management of adverse events
F Gay
Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Ospedale Molinette, Via Genova 3, 10126, Torino, Italy
Med Oncol 27:646-53. 2010
..This chapter will focus on frequency and management of main adverse events in newly diagnosed and relapsed myeloma patients and will provide guidelines for dose reductions and supportive therapy...
- Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients
T Guglielmelli
Department of Clinical and Biological Sciences, University of Turin and San Luigi Hospital, Orbassano, Turin, Italy
Eur J Cancer 47:814-8. 2011
..The aim of this retrospective analysis is to evaluate the impact of thalidomide therapy on lenalidomide response and outcome in relapse or refractory multiple myeloma patients...
- Treatment options for older myeloma patients. From the Multiple Myeloma Research Foundation
Kenneth C Anderson
University of Torino, Torino, Italy
Oncology (Williston Park) 19:447-50. 2005
..multiplemyeloma.org and are published on a regular basis in ONCOLOGY. For more information about the interactive series, see the MMRF ad on page 552...
- Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo
Benedetto Bruno
Division of Hematology, S Giovanni Battista Hospital, University of Torino, Torino, Italy
Blood 113:3375-82. 2009
..http://ClinicalTrials.gov; NCT-00702247.)...
- Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy
F Cavallo
Myeloma Unit, Division of Hematology, University of Torino, AOU S Giovanni Battista, Torino, Italy
Leukemia 25:1627-31. 2011
..In conclusion, we confirm that a short induction with lenalidomide allowed sufficient stem cells collection to perform autologous transplantation in 91% of newly diagnosed patients...
- Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma
S Mariani
Laboratorio di Ematologia Oncologica, Centro di Ricerca in Medicina Sperimentale, Torino, Italy
Leukemia 19:664-70. 2005
..Mevastatin, a specific inhibitor of hydroxy-methylglutaryl-CoA reductase, completely abrogated this antimyeloma activity...
- Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells
P Corradini
Dipartimento di Medicina ed Oncologia Sperimentale, Azienda Ospedaliera San Giovanni Battista Divisione Universitaria di Ematologia, Torino, Italy
J Clin Oncol 17:208-15. 1999
..To describe molecular monitoring of minimal residual disease in patients with myeloma who have achieved complete remission (CR) after autologous or allogeneic transplantation of hematopoietic cells...
- Defibrotide: a review on clinical use and future development
A Larocca
Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliero Universitaria San Giovanni Battista, Torino, Italy
Expert Opin Biol Ther 8:1201-12. 2008
..Defibrotide is a deoxyribonucleic acid derivative that has been developed for the treatment of different vascular disorders...
- Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma
Antonio Palumbo
, Azienda Ospedaliera S Giovanni Battista di Torino, Torino, Italy
Hematol J 5:318-24. 2004
..THAL-DEX is not myelotoxic. It postpones the delivery of effective salvage chemotherapy. This might explain the survival benefit...
- Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial
Antonio Palumbo
, Ospedale Molinette, Via Genova 3, 10126 Torino, Italy
Blood 104:3052-7. 2004
..Intermediate-dose melphalan improves response rate, EFS, and OS in myeloma patients, specifically in those aged 65 to 70. It constitutes a more effective first-line regimen than standard treatment for elderly patients...
- A comparison of allografting with autografting for newly diagnosed myeloma
Benedetto Bruno
San Giovanni Battista Hospital, University of Turin, Turin, Italy
N Engl J Med 356:1110-20. 2007
..In this trial of the treatment of newly diagnosed multiple myeloma, we compared a protocol that entailed a hematopoietic stem-cell autograft followed by an allograft from an HLA-identical sibling with a protocol of tandem autografts...
- Lenalidomide and its role in the management of multiple myeloma
Patrizia Falco
Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Torino, Italy
Expert Rev Anticancer Ther 8:865-74. 2008
..Several trials are testing lenalidomide-based regimens in both newly diagnosed and relapsed patients. This review summarizes the profile of lenalidomide and its current role in the treatment of multiple myeloma...
- Impact of contrast material volume on quantitative assessment of reperfused acute myocardial infarction using delayed-enhancement 64-slice CT: experience in a porcine model
C Martini
Department of Radiology and Cardiology, c o Piastra Tecnica Piano 0, Azienda Ospedaliero Universitaria, Parma, Italy
Radiol Med 115:22-35. 2010
..Our purpose in this study was to compare the impact of contrast material volume in delayed-enhancement computer tomography (CT) imaging for assessing acute reperfused myocardial infarction...
- New developments and treatment in multiple myeloma: new drugs in the treatment of multiple myeloma
M Boccadoro
Divisione Universitaria di Ematologia, Azienda Ospedaliera S. Giovanni Battista di Torino, Torino, Italy
Ann Oncol 13:55-8. 2002
- Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies
Tommaso Caravita
Myeloma Unit, Hematology Department, St Eugenio Hospital, Rome, Italy
Nat Clin Pract Oncol 3:374-87. 2006
..This article summarizes the principal clinical trials of bortezomib and discusses its efficacy in solid and hematologic tumors...
- CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib
Roberto Piva
Center for Experimental Research and Medical Studies CeRMS and Department of Biomedical Sciences and Human Oncology, University of Torino, Via Santena 5, Turin, Italy
Blood 111:2765-75. 2008
....
- New drugs for treatment of multiple myeloma
Benedetto Bruno
Division of Haematology, University of Turin, Department of Medicine and Experimental Oncology, Laboratory of Haematology and Oncology, Centro di Ricerca in Medicina Sperimentale, Ospedale San Giovanni Battista, Italy
Lancet Oncol 5:430-42. 2004
..Here, we discuss the mechanisms of action of these new rational drugs and the preliminary clinical outcomes of a new treatment regimen for MM...
- Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome
Marco Ladetto
Dipartimento di Medicina ed Oncologia Sperimentale, Servizio di Epidemiologia dei Tumori e Biostatistica, Centro di Ricerca in Medicina Sperimentale, Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Torino, Italy
Blood 105:4784-91. 2005
..Future studies will assess COX-2 involvement in other hematologic tumors and its potential use as a therapeutic or chemo-preventive target in onco-hematology...
- The treatment of the elderly multiple myeloma patients
Federica Cavallo
Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Torino, Italy
Leuk Lymphoma 48:469-80. 2007
..In this review we present the data available on the most recent trials dealing with the treatment of elderly MM patients...
- Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests
Marco Ladetto
Divisione Universitaria di Ematologia, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
Exp Hematol 30:529-36. 2002
..In this study, we used a validated real-time polymerase chain reaction (PCR) strategy to evaluate LTC of BM and PBPC samples obtained from MM patients...
- Melphalan and its role in the management of patients with multiple myeloma
Patrizia Falco
Azienda Ospedaliera San Giovanni Battista, Divisione di Ematologia dell Universita di Torino, Torino, Italy
Expert Rev Anticancer Ther 7:945-57. 2007
....
- Dose reduction in spiral CT coronary angiography with dual source equipment. Part II. Dose surplus due to slope-up and slope-down of prospective tube current modulation in a phantom model
C Martini
Dipartimento di Radiologia e Cardiologia, Azienda Ospedaliero Universitaria, Parma, Italy
Radiol Med 115:36-50. 2010
....
- Management of disease- and treatment-related complications in patients with multiple myeloma
Francesca Gay
Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Ospedale Molinette, Turin, Italy
Med Oncol 27:S43-52. 2010
..This chapter will provide an overview of frequency and management of main complications related to the disease itself and to the use of new drugs in newly diagnosed and relapsed patients with myeloma...
- Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates
Vittorio Montefusco
Department of Hematology, Allogeneic Bone Marrow Transplantation Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Leuk Lymphoma 49:2156-62. 2008
..The only variable significantly associated with ONJ was antibiotic prophylaxis (p = 0.012), which had a protective effect. Thus, we speculated that antibiotic prophylaxis may prevent ONJ occurrence after dental procedures...
- Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F San Miguel
Hospital Universitario Salamanca, CIC, IBMCC USAL CSIC, Salamanca, Spain
N Engl J Med 359:906-17. 2008
..This phase 3 study compared the use of melphalan and prednisone with or without bortezomib in previously untreated patients with multiple myeloma who were ineligible for high-dose therapy...
- A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma
Pellegrino Musto
Unit of Hematology and Stem Cell Transplantation, IRCCS Oncology Referral Center of Basilicata, Rionero in Vulture PZ, Italy
Cancer 113:1588-95. 2008
..Few studies published to date have explored the role of BPs in patients with untreated, asymptomatic myeloma (AM). No data are available on the efficacy of zoledronic acid in these patients...
- Successful management of immune thrombocytopenic purpura with thalidomide in a patient with multiple myeloma
Patrizia Falco
Hematol J 5:456-7. 2004
- Efficacy and safety of bortezomib in patients with plasma cell leukemia
Pellegrino Musto
Unit of Hematology and Stem Cell Transplantation, CROB Reference Cancer Center of Basilicata, Rionero in Vulture PZ, Italy
Cancer 109:2285-90. 2007
..Bortezomib is the first proteasome inhibitor approved for the treatment of advanced MM. Currently available information regarding the role of bortezomib in PCL is scanty and derives from anecdotal, single-case reports...
- Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide
Pellegrino Musto
Unit of Hematology and Stem Cell Transplantation, IRCCS Casa Sollievo della Sofferenza Hospital, S Giovanni Rotondo, Italy
Leuk Res 30:283-5. 2006
....
- Thalidomide and lenalidomide: Mechanism-based potential drug combinations
Sonia Vallet
Division of Hematology and Oncology, Cancer Center, Massachusetts General Hospital, Boston, MA, USA
Leuk Lymphoma 49:1238-45. 2008
..Here, we review the mechanism of action of these drugs, providing a rationale for combination studies in order to improve patient outcome and reduce side effects...
- Thromboembolic events with lenalidomide-based therapy for multiple myeloma
Smitha Patiyil Menon
Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Cancer 112:1522-8. 2008
..The purpose was to evaluate the incidence and risk factors of thromboembolism associated with lenalidomide therapy in newly diagnosed myeloma...
- Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma
Massimo Offidani
Clinica di Ematologia Polo Ospedaliero Universitario, Ospedali Riuniti Ancona Università Politecnica delle Marche, Ancona, Italy
Eur J Haematol 78:297-302. 2007
..We performed a case-matched study comparing patients with relapsed/refractory MM receiving thalidomide-dexamethasone alone or the combination thalidomide-dexamethasone-liposomal pegylated doxorubicin...
- Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group
Heinz Ludwig
Department of Medicine, Wilhelminenspital, Montleartstr 37, 1160 Vienna, Austria
Blood 111:4039-47. 2008
....
- Management of newly diagnosed myeloma
S Vincent Rajkumar
Division of Hematology, Department of Internal Medicine, Mayo Clinic and Foundation, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Hematol Oncol Clin North Am 21:1141-56, ix-x. 2007
..Patients who have risk factors, such as deletion 13 or translocation t(4;14) or t(14;16), are candidates for novel, more aggressive treatments...
- The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement
M A Hussein
Department of Hematologic Malignancies, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
Leukemia 22:1479-84. 2008
- MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis
Flavia Pichiorri
Department of Molecular Virology, Ohio State University, Columbus, OH 43210, USA
Proc Natl Acad Sci U S A 105:12885-90. 2008
..In summary, we have described a MM miRNA signature, which includes miRNAs that modulate the expression of proteins critical to myeloma pathogenesis...
- Correlation between fatigue and hemoglobin level in multiple myeloma patients: results of a cross-sectional study
Antonio Palumbo
Haematologica 90:858-60. 2005
..Multiple regression analysis adjusting for several covariates was used. Improved FACT-An scores in women and men were associated with hemoglobin increase up to sex-specific normal values...
